SCHEMBL2901868

SCHEMBL2901868

OCCNC(c1ccc(-c2cccc(F)c2)cc1)c1c[nH]nc1-c1ccco1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R1 P27986 3/20 0.39
PIK3CA P42336 3/20 0.39
AKT1 P31749 1/20 0.37
VSIR Q9H7M9 1/20 0.35
MEN1 O00255 3/20 0.34
ALDH1A1 P00352 3/20 0.34
POLB P06746 3/20 0.34
KMT2A Q03164 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
THRB P10828 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
ESR2 Q92731 2/20 0.34
HPGD P15428 1/20 0.34
MCL1 Q07820 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
CLK4 Q9HAZ1 1/20 0.33
USP2 O75604 1/20 0.33
HSPD1 P10809 1/20 0.33
PTPN7 P35236 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2906827 0.91 AKT1 (0.40) PIK3R1PIK3CAAKT1MEN1ALDH1A1
SCHEMBL2901811 0.84 AKT1 (0.39) AKT1MEN1ALDH1A1POLBKMT2A
SCHEMBL2908485 0.84 AKT1 (0.36) AKT1MEN1ALDH1A1POLBKMT2A
SCHEMBL2902674 0.77 PIK3R1 (0.38) PIK3R1PIK3CAMEN1ALDH1A1POLB
SCHEMBL2903067 0.74 OPRD1 (0.37) PIK3R1PIK3CAMEN1KMT2A
SCHEMBL2902613 0.74 PIK3R1 (0.37) PIK3R1PIK3CAMEN1ALDH1A1POLB
SCHEMBL2908848 0.73 LRRK2 (0.36) PIK3R1PIK3CAMAPTMCL1
SCHEMBL2910374 0.73 ALDH1A1 (0.41) PIK3R1PIK3CAALDH1A1KMT2AKDM4E
Morpholine SCHEMBL2905731 0.71 OPRD1 (0.35) PIK3R1PIK3CAPOLBMAPT
SCHEMBL2902357 0.71 HRH3 (0.37) PIK3R1PIK3CAMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A PIK3R1 2479/4885PIK3CA 3500/4885AKT1 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.